Welcome to our dedicated page for Vistagen Therapeutics SEC filings (Ticker: VTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vistagen Therapeutics, Inc. filings document regulatory and corporate events for a Nasdaq-listed late clinical-stage biopharmaceutical company. Recent Form 8-K disclosures cover clinical program updates for fasedienol in the PALISADE social anxiety disorder program, FDA-related developments for refisolone under an IND application, and Regulation FD materials such as corporate presentations.
The company’s filings also record governance and capital-structure matters, including board departures, Audit Committee composition and Nasdaq listing-rule compliance, employee retention awards under the Amended and Restated 2019 Omnibus Equity Incentive Plan, and workforce and cash-management actions tied to clinical-development priorities.
Great Point Partners and two principals report beneficial ownership of 2,055,834 shares of Vistagen Therapeutics (VTGN), representing 6.59% of the outstanding common stock. The reported interest consists of warrants exercisable into common stock and is calculated using 29,157,733 shares outstanding as reported by the issuer.
The filing is a joint Schedule 13G/A by Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, each disclosing shared voting and dispositive power over 2,055,834 shares. The warrants contain a Beneficial Ownership Cap that limits exercise so the holder would not exceed 9.99% ownership, and the reporting persons disclaim beneficial ownership of underlying shares except to the extent of pecuniary interest.
Vistagen Therapeutics, Inc. (VTGN) filed a Form 4 on 25-Jun-2025 detailing an equity award to its newly appointed Chief Corporate Development Officer, Elissa S. Cote. On 23-Jun-2025 Ms. Cote received 150,000 stock options with an exercise price of $1.96 per share and an expiration date of 23-Jun-2035. The transaction is coded “A,” indicating an acquisition at no cost to the insider.
The options vest 25 % on 23-Jun-2026, with the remaining 75 % vesting in equal monthly installments over the subsequent 36 months, resulting in full vesting three years after the initial cliff. Following the grant, Ms. Cote beneficially owns 150,000 derivative securities and reported no ownership of, or transactions in, non-derivative common shares.
This award forms part of her employment package and aligns her long-term incentives with shareholder interests. Although the grant introduces potential dilution of roughly 150,000 shares, it does not involve any insider selling and therefore has minimal immediate market impact.
Vistagen Therapeutics (VTGN) has filed a Form 3 (Initial Statement of Beneficial Ownership) for Elissa S. Cote, who has been appointed as the company's Chief Corporate Development Officer. The filing date is June 28, 2025, with the triggering event occurring on June 23, 2025.
Key details from the filing:
- The reporting person currently owns no securities of the company, either direct or indirect
- No derivative securities (options, warrants, etc.) are reported as beneficially owned
- This is an individual filing, not a joint/group submission
- The filing address is listed as 343 Allerton Avenue, South San Francisco, CA 94080
This Form 3 filing is a standard regulatory requirement for new officers, directors, and 10% shareholders to disclose their initial ownership positions in the company's securities.